MetaCap

Atara Biotherapeutics Inc. (ATRA)

NASDAQ: ATRAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

6.33-0.01 (-0.16%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ATRA stock chart

Technical analysis

Key statistics

All statistics
Market cap
$64.49M
EPS (TTM)
-$1.12
52-week range
3.92 – 19.15
Day range
6.25 – 6.85
Volume / Avg
36.42K / 35.46K
Beta
—

52-week range

$3.92$19.15

ATRA stock today

On Nov 20, ATRA ended the session at $6.33, shedding $0.01 (0.16%), versus the S&P 500's 3.70% decline. At this level, ATRA sits near the bottom of its 52-week range of $3.92 to $19.15: 66.9% below the high, set on Jan 5, 2026 and 61.5% above the low. ATRA is down 65.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 53.7%.

Atara Biotherapeutics has posted a net loss over the last twelve months (EPS of -$1.12), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Atara Biotherapeutics

Company profile

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Anhco Nguyen Ph.D.
Headquarters
Thousand Oaks, CA
Employees
10
IPO year
2014

Financial highlights

Full financials

In fiscal 2025, Atara Biotherapeutics generated $120.8 million in revenue, down 6.3% from fiscal 2024, its first annual decline since 2023. Net income was $32.7 million, for a net margin of 27.1% versus a median of -359.1% in the prior 5 years. Operating margin was 29.7%.

Atara Biotherapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$120.77M$128.94M$8.57M$63.57M—
Growth-6.33%+1404.02%-86.51%——
Net income$32.69M$-85.40M$-276.13M$-228.30M$-340.14M
EPS (diluted)$2.57$-11.41$-65.19$-2.24$-3.63

Analyst forecast

Forecast

Consensus (3 analysts)

buy

Avg. price target

$13.67+115.96%

  • Strong buy 0
  • Buy 2
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $10.00High $18.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 11, 2026
EPS actual vs est.
$-0.15 vs —

ATRA news

All ATRA news

Atara Biotherapeutics peers

Health Care sector
ATRA peer companies
CompanyPrice% ChgMarket capCompare
TNYATenaya Therapeutics Inc.0.2866-3.99%$65.32Mvs ATRA
NMRANeumora Therapeutics Inc.0.3339-3.78%$63.01Mvs ATRA
CRDFCardiff Oncology Inc.0.8528-4.46%$66.34Mvs ATRA
CSBRChampions Oncology Inc.4.34-1.36%$60.41Mvs ATRA
CHRSCoherus Oncology Inc.0.3698-4.47%$57.15Mvs ATRA
OKYOOKYO Pharma Limited1.07-7.76%$56.15Mvs ATRA
CGTXCognition Therapeutics Inc.0.5822-3.06%$55.37Mvs ATRA
AVXLAnavex Life Sciences Corp.0.5915-11.39%$54.83Mvs ATRA

Indexes, lists and sector

Atara Biotherapeutics stock FAQ

What is Atara Biotherapeutics's stock price today?

ATRA last traded at $6.33 as of Nov 20, 4:00 PM EST, down 0.16% on the day. Prices are delayed at least 15 minutes.

Does Atara Biotherapeutics pay a dividend?

No. Atara Biotherapeutics does not currently pay a regular cash dividend.

Who is Atara Biotherapeutics's CEO?

Dr. Anhco Nguyen Ph.D. is the chief executive officer of Atara Biotherapeutics Inc., which has about 10 employees.

Has ATRA ever split its stock?

Yes. The most recent ATRA stock split was a 1-for-25 split on Jun 20, 2024.

What is the ATRA 52-week high?

The 52-week high for ATRA is $19.15 and the 52-week low is $3.92. The stock is currently 66.9% below its high.

Compare ATRA